open access

Vol 22, No 1 (2015)
Original articles
Published online: 2015-02-24
Get Citation

Newly impaired glucose metabolism and prognosis after percutaneous revascularization

Manuel F. Jiménez-Navarro, Julia Fernández-Pastor, Lourdes Garrido-Sánchez, María J. Molina-Mora, Carmen Ortiz-García, Juan H. Alonso-Briales, Alejandro Pérez-Cabeza, Jose M. Hernández-García, Eduardo de Teresa-Galván, Francisco J. Tinahones
DOI: 10.5603/CJ.a2014.0024
·
Pubmed: 24671899
·
Cardiol J 2015;22(1):44-51.

open access

Vol 22, No 1 (2015)
Original articles
Published online: 2015-02-24

Abstract

Background: Clinical practice guidelines recommend ad hoc screening of diabetes in patients admitted for macrovascular disease; however, these recommendations are rarely followed in real practice. This study was undertaken to assess whether impaired glucose metabolism, newly diagnosed after percutaneous coronary intervention (PCI) or known diabetes, provides prognostic information.

Methods: We studied 374 patients who underwent PCI. An oral glucose tolerance test was carried out in the known non-diabetic patients with fasting glucose < 7 mmol/L.

Results: Eighty-one percent of the patients presented impaired glucose metabolism, from which 35.3% were previously diagnosed with diabetics, 21.4% were newly detected diabetics, and 24.3% were pre-diabetics. After a mean follow-up of 35.8 ± 13.4 months, only a known history of diabetes was an independent predictor of revascularization (OR = 2.03, p = 0.025), non-fatal acute myocardial infarction (OR = 2.70, p = 0.029) and readmission due to heart failure during the follow-up (OR = 3.82, p = 0.022).

Conclusions: Screening for impaired glucose metabolism after PCI permits the detection of a high proportion of patients with abnormal glucose regulations. However, previously known diabetes remains the only independent predictor of cardiovascular events in the follow-up.

Abstract

Background: Clinical practice guidelines recommend ad hoc screening of diabetes in patients admitted for macrovascular disease; however, these recommendations are rarely followed in real practice. This study was undertaken to assess whether impaired glucose metabolism, newly diagnosed after percutaneous coronary intervention (PCI) or known diabetes, provides prognostic information.

Methods: We studied 374 patients who underwent PCI. An oral glucose tolerance test was carried out in the known non-diabetic patients with fasting glucose < 7 mmol/L.

Results: Eighty-one percent of the patients presented impaired glucose metabolism, from which 35.3% were previously diagnosed with diabetics, 21.4% were newly detected diabetics, and 24.3% were pre-diabetics. After a mean follow-up of 35.8 ± 13.4 months, only a known history of diabetes was an independent predictor of revascularization (OR = 2.03, p = 0.025), non-fatal acute myocardial infarction (OR = 2.70, p = 0.029) and readmission due to heart failure during the follow-up (OR = 3.82, p = 0.022).

Conclusions: Screening for impaired glucose metabolism after PCI permits the detection of a high proportion of patients with abnormal glucose regulations. However, previously known diabetes remains the only independent predictor of cardiovascular events in the follow-up.

Get Citation

Keywords

diabetes, impaired glucose metabolism, percutaneous coronary intervention

About this article
Title

Newly impaired glucose metabolism and prognosis after percutaneous revascularization

Journal

Cardiology Journal

Issue

Vol 22, No 1 (2015)

Pages

44-51

Published online

2015-02-24

DOI

10.5603/CJ.a2014.0024

Pubmed

24671899

Bibliographic record

Cardiol J 2015;22(1):44-51.

Keywords

diabetes
impaired glucose metabolism
percutaneous coronary intervention

Authors

Manuel F. Jiménez-Navarro
Julia Fernández-Pastor
Lourdes Garrido-Sánchez
María J. Molina-Mora
Carmen Ortiz-García
Juan H. Alonso-Briales
Alejandro Pérez-Cabeza
Jose M. Hernández-García
Eduardo de Teresa-Galván
Francisco J. Tinahones

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl